Pharmacopsychiatry 2010; 43(2): 50-57
DOI: 10.1055/s-0029-1239539
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Effect of Aripiprazole on Cognition in the Treatment of Patients with Schizophrenia

M. Riedel1 , I. Spellmann1 , R. Schennach-Wolff1 , R. Musil1 , S. Dehning1 , A. Cerovecki1 , M. Opgen-Rhein1 , J. Matz1 , F. Seemüller1 , M. Obermeier1 , E. Severus1 , R. R. Engel1 , N. Müller1 , H.-J. Möller1
  • 1Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany
Further Information

Publication History

received 16.04.2009 revised 30.07.2009

accepted 08.09.2009

Publication Date:
10 December 2009 (eFirst)

Abstract

Background: The aim of this study was to assess the cognitive effects of aripiprazole in inpatients with schizophrenia.

Methods: This was an investigator-initiated, open label eight-week trial evaluating 56 inpatients with the DSM-IV diagnosis of schizophrenia. Efficacy was assessed weekly using the Positive and Negative Syndrome Scale (PANSS) and tolerability was assessed each week using the Udvalg for Klinske Undersogelser side effect rating scale (UKU). Cognitive function was assessed at baseline, week 4 and week 8.

Results: Aripiprazole showed significant improvement in PANSS total score and all subscores between baseline and endpoint visit. The substance was very well tolerated. Patients improved significantly in verbal memory, reaction time and reaction quality/attention from baseline to week eight. Furthermore, mean z-values of individual cognitive domains summarized in a global cognitive index improved significantly from baseline to week eight.

Discussion: Our results suggest that aripiprazole provides a valuable treatment option for patients with schizophrenia.

References

Correspondence

R. Schennach-Wolff, MD 

Department of Psychiatry

Ludwig-Maximilians-University

Nussbaumstraße 7

80336 Munich

Germany

Phone: +49/89/5160 58 69

Fax: +49/89/5160 58 57

Email: Rebecca.Schennach-Wolff@med.uni-muenchen.de